BTK and B-cell chronic lymphocytic leukemia: The ongoing phase 3 CLL17 trial (NCT04608318) is investigating non-inferiority of FD ibrutinib-venetoclax or obinutuzumab-venetoclax compared with standard-of-care single-agent continuous BTKi inhibitor in first-line treatment of CLL and is anticipated to provide direct head-to-head comparisons on the relative efficacy and safety of FD treatments compared with continuous BTK inhibitor monotherapy.